Welcome to MutualFunds.com. Please help us personalize your experience.
Your personalized experience is almost ready.
Thank you!
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission, we hope you enjoy your experience
The Franklin Biotechnology Discovery Fund Class A (FBDIX) is an actively managed fund that specializes in the health care sector. FBDIX specifically targets those biotech companies engaged in new drug development and marketing. This includes firms in genomics research, genetic engineering and gene expression therapy. Managers use a bottom-up, fundamental approach to picking biotech stocks for FBDIX’s assets and lean heavily on stocks with competitive profiles and large market opportunities for their drugs.
Fees for FBDIX are considered low. However, given its specialized nature, the fund is only suitable as a satellite position. The fund is internally managed by Franklin Advisers.
Sign up for Advisor Access to receive email updates about FBDIX competitors, news, CE accredited webcasts and more.
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 32.1% | 9.8% | 47.8% | 5.98% |
| 1 Yr | 16.4% | -15.7% | 26.6% | 8.55% |
| 3 Yr | 5.3%* | -12.3% | 24.7% | 69.09% |
| 5 Yr | -1.6%* | -10.9% | 14.5% | 63.81% |
| 10 Yr | 11.0%* | -1.9% | 17.8% | 31.82% |
* Annualized
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2018 | -18.6% | -25.3% | 21.5% | 90.09% |
| 2017 | 16.0% | -10.8% | 43.9% | 51.38% |
| 2016 | -20.7% | -31.6% | 6.9% | 77.36% |
| 2015 | -3.0% | -20.4% | 13.8% | 60.19% |
| 2014 | 28.6% | -5.8% | 31.5% | 10.42% |
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 32.1% | 9.8% | 47.8% | 5.98% |
| 1 Yr | 16.4% | -15.7% | 35.3% | 10.26% |
| 3 Yr | 7.7%* | -12.3% | 27.2% | 67.27% |
| 5 Yr | 2.3%* | -10.9% | 16.6% | 59.05% |
| 10 Yr | 15.6%* | -1.9% | 17.9% | 25.00% |
* Annualized
| Period | FBDIX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2018 | -18.6% | -25.3% | 22.2% | 90.99% |
| 2017 | 18.8% | -10.8% | 45.8% | 56.88% |
| 2016 | -17.1% | -26.4% | 8.7% | 73.58% |
| 2015 | 5.7% | -16.6% | 15.2% | 56.31% |
| 2014 | 33.8% | -5.8% | 36.7% | 14.58% |
| FBDIX | Category Low | Category High | FBDIX % Rank | |
|---|---|---|---|---|
| Net Assets | 1.08 B | 3.25 M | 47.5 B | 49.61% |
| Number of Holdings | 75 | 26 | 388 | 56.69% |
| Net Assets in Top 10 | 554 M | 913 K | 17.4 B | 35.43% |
| Weighting of Top 10 | 51.14% | 21.3% | 77.1% | 27.56% |
| Weighting | Return Low | Return High | FBDIX % Rank | |
|---|---|---|---|---|
| Stocks | 97.85% | 90.21% | 103.54% | 53.54% |
| Cash | 1.98% | 0.00% | 9.79% | 36.22% |
| Other | 0.17% | -27.41% | 5.17% | 30.71% |
| Preferred Stocks | 0.00% | 0.00% | 1.08% | 24.41% |
| Convertible Bonds | 0.00% | 0.00% | 1.54% | 18.11% |
| Bonds | 0.00% | 0.00% | 20.60% | 18.11% |
| Weighting | Return Low | Return High | FBDIX % Rank | |
|---|---|---|---|---|
| Healthcare | 97.76% | 56.22% | 99.75% | 40.16% |
| Energy | 0.09% | 0.00% | 0.43% | 1.57% |
| Utilities | 0.00% | 0.00% | 0.00% | 10.24% |
| Technology | 0.00% | 0.00% | 16.35% | 44.88% |
| Real Estate | 0.00% | 0.00% | 5.81% | 18.90% |
| Industrials | 0.00% | 0.00% | 2.40% | 21.26% |
| Financial Services | 0.00% | 0.00% | 5.93% | 32.28% |
| Communication Services | 0.00% | 0.00% | 1.02% | 14.17% |
| Consumer Defense | 0.00% | 0.00% | 34.83% | 20.47% |
| Consumer Cyclical | 0.00% | 0.00% | 10.49% | 18.90% |
| Basic Materials | 0.00% | 0.00% | 1.94% | 32.28% |
| Weighting | Return Low | Return High | FBDIX % Rank | |
|---|---|---|---|---|
| US | 88.97% | 58.61% | 99.93% | 20.47% |
| Non US | 8.88% | 0.00% | 40.52% | 79.53% |
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.02% | 0.10% | 4.94% | 68.38% |
| Management Fee | 0.59% | 0.09% | 1.30% | 16.54% |
| 12b-1 Fee | 0.25% | 0.00% | 1.00% | 20.83% |
| Administrative Fee | 0.15% | 0.01% | 0.40% | 55.36% |
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | 5.50% | 2.50% | 5.75% | 53.85% |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 0.75% | 2.00% | N/A |
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| FBDIX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 28.62% | 0.00% | 341.00% | 19.49% |
| FBDIX | Category Low | Category High | FBDIX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 3.95% | 25.98% |
| FBDIX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Quarterly | Annually |
| FBDIX | Category Low | Category High | FBDIX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.67% | -2.24% | 2.12% | 76.92% |
| FBDIX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
| Date | Amount |
|---|---|
| Dec 19, 2016 | $1.728 |
| Dec 19, 2012 | $0.069 |
| Dec 30, 2011 | $0.515 |
Start Date
Tenure
Tenure Rank
Sep 15, 1997
22.22
22.2%
Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
Start Date
Tenure
Tenure Rank
Sep 15, 2015
4.21
4.2%
Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.
Start Date
Tenure
Tenure Rank
Sep 01, 2018
1.25
1.3%
Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.34 | 22.22 | 9.78 | 19.59 |
TAXATION
For mutual fund investors, taxes are inevitable. Even if you’re a long-term buy...
MUTUAL FUND EDUCATION
Many investors assume that changes in a mutual fund’s net asset value (NAV)...
MUTUAL FUND EDUCATION
For investors looking to add mutual funds to their portfolio, they need to...
